Aydogdu, O. Et Al. 2022. Treatment with the soluble guanylate cyclase activator BAY 60–2770 normalizes bladder function in an in vivo rat model of chronic prostatitis. European Journal of Pharmacology , vol.927 .

Aydogdu, O., Perez, F., Aronsson, P., UYAR GÖÇÜN, F. P., Carlsson, T., Sandner, P., ... Patel, B.(2022). Treatment with the soluble guanylate cyclase activator BAY 60–2770 normalizes bladder function in an in vivo rat model of chronic prostatitis. European Journal of Pharmacology , vol.927.

Aydogdu, Ozgu Et Al. "Treatment with the soluble guanylate cyclase activator BAY 60–2770 normalizes bladder function in an in vivo rat model of chronic prostatitis," European Journal of Pharmacology , vol.927, 2022

Aydogdu, Ozgu Et Al. "Treatment with the soluble guanylate cyclase activator BAY 60–2770 normalizes bladder function in an in vivo rat model of chronic prostatitis." European Journal of Pharmacology , vol.927, 2022

Aydogdu, O. Et Al. (2022) . "Treatment with the soluble guanylate cyclase activator BAY 60–2770 normalizes bladder function in an in vivo rat model of chronic prostatitis." European Journal of Pharmacology , vol.927.

@article{article, author={Ozgu Aydogdu Et Al. }, title={Treatment with the soluble guanylate cyclase activator BAY 60–2770 normalizes bladder function in an in vivo rat model of chronic prostatitis}, journal={European Journal of Pharmacology}, year=2022}